Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Peptic Ulcer Drugs Market – Insights

Peptic ulcers are open sores that develop on the inside lining of the stomach and the upper portion of the small intestine. There are two types of peptic ulcers that include gastric ulcers and duodenal ulcers. Peptic ulcer disease (PUD) is a result of reduction in the thick layer of mucus that protects the stomach from digestive juices.

The global peptic ulcer drugs market is estimated to account for US$ 45,951.2 Mn in terms of value by the end of 2027

Global Peptic Ulcer Drugs Market: Drivers

Increasing prevalence of peptic ulcers is a major factor boosting growth of the global peptic ulcer drugs market over the forecast period. For instance, according to the study, ‘A36 The Global Incidence of Peptic Ulcer Disease and Its Complications at The Turn Of The 21st Century: A Systematic Review’, published in the Journal of the Canadian Association of Gastroenterology in March 2018, Spain recorded the highest annual incidence of all PUD (complicated and uncomplicated) with 141.8 cases per 100,000 persons.

Moreover, change in lifestyle such as stress, diet, and high rate of smoking is also expected to propel growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018.

North America region held dominant position in the global peptic ulcer drugs market in 2018, accounting for 41.4% share in terms of volume, followed by Europe.

Figure 1. Global Peptic Ulcer Drugs Market Value (US$ Mn), by Region, 2018

Peptic Ulcer Drugs  | Coherent Market Insights

Global Peptic Ulcer Drugs Market: Restraints

Prolonged use of peptic ulcer drugs such as proton pump inhibitors and antibiotics may lead to increased risk of hip bone fracture as the ability to absorb calcium and iron decreases. Other side effects include, risk of opportunistic infections with S. pneumonia and C. defficile, owing to diminished natural gut flora. Such scenario is expected to hamper growth of the global peptic ulcer drugs market.

Moreover, wide availability of generic drugs and poor patient compliance to medication in some countries is also expected to hamper growth of the market.

Global Peptic Ulcer Drugs Market: Opportunities

Key players in the market can focus on personalized treatment and management of patients suffering from PUD in order to enhance their market share. For instance, in July 2019, in a study published in the Journal of Clinical Medicine (MDPI), researchers from Institute of Medical Microbiology, Switzerland, concluded that next generation sequencing technology may facilitate rapid monitoring of virulence determinants in H. pylori, which may prove beneficial in personalized treatment and management of patients suffering from PUD.

Moreover, high doses of nonsteroidal anti-inflammatory drug (NSAIDs) is associated with risk of recurrent PUD. Therefore, market players may focus on R&D in H. pylori eradication therapy as it has the potential to reduce the risk of recurrent PUD among NSAID users.

Peptic Ulcer Drugs  | Coherent Market Insights

Proton Pump Inhibitors segment in the global peptic ulcer drugs market was valued at US$ 24,799.4 Mn in 2018 and is expected to reach US$ 31,895.7 Mn by 2027 at a CAGR of 2.8% during the forecast period.

Market Trends/Key Takeaways

The use of AI in diagnosis of peptic ulcers is a major trend in the global peptic ulcer drugs market. For instance, in December 2019, Inspirata, a US-based cancer informatics and digital pathology provider, partnered with DeePathology on Artificial Intelligence (AI)-based Helicobacter Pylori (H Pylori) pathology testing.

Key players in the market are focused on assessing the efficacy of potassium-competitive acid blocker in combination therapy for the treatment of PUD. For instance, in December 2019, Phathom Pharmaceuticals initiated pivotal phase III trial that is expected to assess the efficacy of Vonoprazan in combination with Amoxicillin against Vonoprazan in combination with Amoxicillin and Clarithromycin for the successful eradication of H. pylori infection.

Regulations

The U.S. FDA is currently reviewing the risk of Clostridium difficile–associated diarrhea (CDAD) in users of histamine H2 receptor blockers. H2 receptor blockers are used for the treatment of gastro esophageal reflux disease (GERD), stomach and small intestine ulcers, and heartburn.

Global Peptic Ulcer Drugs Market: Competitive Landscape

Major players operating in the global peptic ulcer drugs market include, Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Abbott Laboratories, AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline plc.

Global Peptic Ulcer Drugs Market: Key Developments

Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in November 2019, RedHill Biopharma received the U.S. FDA approval for Talicia, a treatment for Helicobacter pylori (H. pylori) infection in adults, regardless of ulcer status.

In October 2019, Novitium Pharma LLC recalled ranitidine hydrochloride capsules (indicated for the treatment of duodenal ulcer) in the U.S., owing to potential N-Nitrosodimethylamine (NDMA) (a probable human carcinogen) amounts above levels established by the U.S. FDA.

Peptic ulcers are also classed as stomach ulcers or gastric ulcers can cause abdominal pain and discomfort in the abdomen. There are two types of peptic ulcer found gastric ulcer and duodenal ulcer. Gastric ulcers are commonly found in the inner lining of the stomach whereas the duodenal ulcers are formed in small intestines. Peptic ulcers are caused due to reduction of mucus layer that protects the stomach from digestive juices. Major symptoms of peptic ulcers constitute of burping, nausea, vomiting, loss in appetite, and etc. The treatment of peptic ulcers depend on the type of ulcer and the treatment regime mostly comprises of proton pump inhibitors, and antibiotics.

Key features of the study:

  • This report provides in-depth analysis of the Peptic Ulcer Drugs market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global Peptic Ulcer Drugs market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Abbott Laboratories, AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Peptic Ulcer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Peptic Ulcer Drugs market

Detailed Segmentation:

  • Peptic Ulcer Drugs Market, By Product Type:
    • Proton Pump Inhibitors
    • Potassium-Competitive Acid Blocker (P-CAB)
    • Antacids
    • H2- Antagonists
    • Antibiotics
    • Ulcer Protective
  • Peptic Ulcer Drugs Market, By Disease Indication:
    • Gastritis
    • Gastric Ulcer
    • Duodenal Ulcer
    • Gastroesophageal Reflux Disease (GERD)
  • Peptic Ulcer Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Private Clinics
    • Drug Stores
    • Retail Pharmacies
    • E-Commerce
  • Peptic Ulcer Drugs Market, By Region:
    • North America
      • By Product Type:
        • Proton Pump Inhibitors
        • Potassium-Competitive Acid Blocker (P-CAB)
        • Antacids
        • H2- Antagonists
        • Antibiotics
        • Ulcer Protective
      • By Disease Indication
        • Gastritis
        • Gastric Ulcer
        • Duodenal Ulcer
        • Gastroesophageal Reflux Disease (GERD)
      • By Distribution Channel
        • Hospital Pharmacies
        • Private Clinics
        • Drug Stores
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Proton Pump Inhibitors
        • Potassium-Competitive Acid Blocker (P-CAB)
        • Antacids
        • H2- Antagonists
        • Antibiotics
        • Ulcer Protective
      • By Disease Indication
        • Gastritis
        • Gastric Ulcer
        • Duodenal Ulcer
        • Gastroesophageal Reflux Disease (GERD)
      • By Distribution Channel
        • Hospital Pharmacies
        • Private Clinics
        • Drug Stores
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Proton Pump Inhibitors
        • Potassium-Competitive Acid Blocker (P-CAB)
        • Antacids
        • H2- Antagonists
        • Antibiotics
        • Ulcer Protective
      • By Disease Indication
        • Gastritis
        • Gastric Ulcer
        • Duodenal Ulcer
        • Gastroesophageal Reflux Disease (GERD)
      • By Distribution Channel
        • Hospital Pharmacies
        • Private Clinics
        • Drug Stores
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Proton Pump Inhibitors
        • Potassium-Competitive Acid Blocker (P-CAB)
        • Antacids
        • H2- Antagonists
        • Antibiotics
        • Ulcer Protective
      • By Disease Indication
        • Gastritis
        • Gastric Ulcer
        • Duodenal Ulcer
        • Gastroesophageal Reflux Disease (GERD)
      • By Distribution Channel
        • Hospital Pharmacies
        • Private Clinics
        • Drug Stores
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Proton Pump Inhibitors
        • Potassium-Competitive Acid Blocker (P-CAB)
        • Antacids
        • H2- Antagonists
        • Antibiotics
        • Ulcer Protective
      • By Disease Indication
        • Gastritis
        • Gastric Ulcer
        • Duodenal Ulcer
        • Gastroesophageal Reflux Disease (GERD)
      • By Distribution Channel
        • Hospital Pharmacies
        • Private Clinics
        • Drug Stores
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Proton Pump Inhibitors
        • Potassium-Competitive Acid Blocker (P-CAB)
        • Antacids
        • H2- Antagonists
        • Antibiotics
        • Ulcer Protective
      • By Disease Indication
        • Gastritis
        • Gastric Ulcer
        • Duodenal Ulcer
        • Gastroesophageal Reflux Disease (GERD)
      • By Distribution Channel
        • Hospital Pharmacies
        • Private Clinics
        • Drug Stores
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Daewoong Pharmaceutical Co., Ltd. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Takeda Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • AstraZeneca plc.
    • RedHill Biopharma
    • Cadila Healthcare Ltd.
    • Novitium Pharma LLC.
    • Boehringer Ingelheim GmbH
    • Eisai Co. Ltd.
    • Yuhan Corporation
    • GlaxoSmithKline plc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippets, By Disease Indication
      • Market Snippets, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Regulatory Scenario
    • Mergers and Acquisitions
  4. Global Peptic Ulcer Drugs Market, By Product Type, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Proton Pump Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Potassium-Competitive Acid Blocker (P-CAB)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Antacids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • H2- Antagonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ulcer Protective
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Peptic Ulcer Drugs Market, By Disease Indication, 2019 – 2027, (US$ Mn)
    • Gastitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Gastric Ulcer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Duodenal Ulcer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Gastroesophageal Reflux Disease (GERD)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Peptic Ulcer Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Mn)
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Private Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Drug Stores
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • E-Commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Peptic Ulcer Drugs Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • Daewoong Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AstraZeneca plc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • RedHill Biopharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cadila Healthcare Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novitium Pharma LLC.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eisai Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Yuhan Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 42 market data tables and 44 figures on “Peptic Ulcer Drugs Market - Global forecast to 2027”.

Frequently Asked Questions

The global peptic ulcer drugs market is estimated to reach US$ 45,951.2 Mn , in terms of value by the end of 2027 .
Major players operating in the global peptic ulcer drugs market include Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Abbott Laboratories, AstraZeneca plc., RedHill Biopharma, Cadila Healthcare Ltd., Novitium Pharma LLC, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline plc.
Prolonged usage of peptic ulcer drugs such as proton pump inhibitors and antibiotics may augment risk of hip bone fracture, which is one of the major factors that is expected to hamper growth of the market over the forecast period.
The increasing prevalence of peptic ulcers, and change in lifestyle such as stress, diet, and high rate of smoking are some of the major factors that are expected to propel growth of the market over the forecast period.
Application of AI in the diagnosis of peptic ulcers is a major trend that has been observed in the global peptic ulcer drugs market.
Among regions, North America held a dominant position in the global peptic ulcer drugs market in 2018 , accounting for 41.4% share , in terms of volume, followed by Europe.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner